Myung In Pharma Co., Ltd. (Ticker: 317450 KS) is a South Korea–based specialty and generic pharmaceutical company focused on CNS therapies, including treatments for Parkinson’s disease, schizophrenia and depression, along with well-known OTC brands. Myung In Pharma plans to list on the KOSPI on Oct. 1, 2025, offering 3.40 million new common shares at KRW 45,000–58,000 per share to raise KRW 197.20 billion (about USD 140.92 million). The company manufactures finished pharmaceuticals and active pharmaceutical ingredients, serving the domestic and export markets. KB Securities is the sole manager. A note in the filing indicates 680,000 shares are locked up for an employee stock ownership plan for one year after the deposit date. Subscription is scheduled for Sept. 18–19, 2025, with expected pricing on Sept. 17, 2025.